GSK
GSK
896 hedge funds and large institutions have $16.7B invested in GSK in 2025 Q3 according to their latest regulatory filings, with 100 funds opening new positions, 323 increasing their positions, 308 reducing their positions, and 79 closing their positions.
105% more call options, than puts
Call options by funds: $267M | Put options by funds: $130M
44% more funds holding in top 10
Funds holding in top 10: 9 → 13 (+4)
27% more first-time investments, than exits
New positions opened: 100 | Existing positions closed: 79
15% more capital invested
Capital invested by funds: $14.5B → $16.7B (+$2.15B)
5% more repeat investments, than reductions
Existing positions increased: 323 | Existing positions reduced: 308
1% more funds holding
Funds holding: 891 → 896 (+5)
0.51% more ownership
Funds ownership: 18.45% → 18.97% (+0.51%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$201M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$76.8M |
| 3 |
MNA
Manning & Napier Advisors
Fairport,
New York
|
+$65.2M |
| 4 |
Holocene Advisors
New York
|
+$58.2M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$53.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$121M |
| 2 |
Primecap Management
Pasadena,
California
|
-$76.6M |
| 3 |
CCMG
Clark Capital Management Group
Philadelphia,
Pennsylvania
|
-$68.3M |
| 4 |
AOI
Auto-Owners Insurance
Lansing,
Michigan
|
-$35.4M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$23.2M |
GSK Hedge Fund Activity: Q3 2025 in Review
896 of the 7,639 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q3 2025, worth a combined $16.7B — up 15% from $14.5B a quarter earlier.
Buyers outnumbered sellers: 100 funds opened new GSK positions and 79 closed out — a net gain of 21 holders — while 323 added to existing stakes and 308 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $201M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $121M sold.
- 896 institutional investors held GSK (GSK) as of Q3 2025, up from 891 in Q2 2025.
- Funds reported $16.7B of GSK stock for Q3 2025, up 15% quarter-over-quarter.
- 100 funds opened new GSK positions in Q3 2025 and 79 closed out, a net change of +21 holders.
- The largest GSK buyer in Q3 2025 was Fidelity Investments, an estimated $201M added.
- The largest GSK seller in Q3 2025 was Alyeska Investment Group, an estimated $121M sold.
Based on aggregated 13F filings for Q3 2025.